Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Huber

Showing results (511-520 of 539) with videos related to

Pageof 54
Sort By:
JCO Oncology Practice|May 12, 2025
High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple MyelomaMark Aaron Fiala, Mengmeng Ji, Michael Slade, et al.
Leukemia|November 9, 2000
Deletions of chromosome 13q in monoclonal gammopathy of undetermined significanceR Königsberg, J Ackermann, H Kaufmann, et al.
Investigational New Drugs|June 9, 1999
Phase I study of paclitaxel administered by ten-day continuous infusionR J Shade, K M Pisters, M H Huber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
The impact of hemoglobin levels on fatigue and quality of life in cancer patientsB Holzner, G Kemmler, R Greil, et al.
Science (New York, N.Y.)|May 23, 2002
Ascent of dinosaurs linked to an iridium anomaly at the Triassic-Jurassic boundaryP E Olsen, D V Kent, H-D Sues, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1995
Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancerM H Huber, S M Lippman, S E Benner, et al.
Microorganisms|July 8, 2020
Malaria Elimination in Costa Rica: Changes in Treatment and Mass Drug AdministrationLuis F Chaves, John H Huber, Obdulio Rojas Salas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung CancerG Krajnik, A Mohn-Staudner, J Thaler, et al.
Blood|July 29, 1998
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapyJ Drach, J Ackermann, E Fritz, et al.
Annals of Hematology|June 1, 1996
Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study GroupJ Thaler, G Gastl, T Fluckinger, et al.
Pageof 54

Showing results (511-520 of 539) with videos related to

Sort By:
Pageof 54
JCO Oncology Practice|May 12, 2025
High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple MyelomaMark Aaron Fiala, Mengmeng Ji, Michael Slade, et al.
Leukemia|November 9, 2000
Deletions of chromosome 13q in monoclonal gammopathy of undetermined significanceR Königsberg, J Ackermann, H Kaufmann, et al.
Investigational New Drugs|June 9, 1999
Phase I study of paclitaxel administered by ten-day continuous infusionR J Shade, K M Pisters, M H Huber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
The impact of hemoglobin levels on fatigue and quality of life in cancer patientsB Holzner, G Kemmler, R Greil, et al.
Science (New York, N.Y.)|May 23, 2002
Ascent of dinosaurs linked to an iridium anomaly at the Triassic-Jurassic boundaryP E Olsen, D V Kent, H-D Sues, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1995
Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancerM H Huber, S M Lippman, S E Benner, et al.
Microorganisms|July 8, 2020
Malaria Elimination in Costa Rica: Changes in Treatment and Mass Drug AdministrationLuis F Chaves, John H Huber, Obdulio Rojas Salas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung CancerG Krajnik, A Mohn-Staudner, J Thaler, et al.
Blood|July 29, 1998
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapyJ Drach, J Ackermann, E Fritz, et al.
Annals of Hematology|June 1, 1996
Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study GroupJ Thaler, G Gastl, T Fluckinger, et al.
Pageof 54